Journal Watch · Science Advances · 2026

Programming angiogenesis with tunable assemblies of multifunctional peptides.

This strategy establishes a modular platform for engineering instructive microenvironments that bridge molecular design and tissue-scale functionality.

Dodd-O J, Shadpoor B, Roy A et al.Science Advances3 min readPharma relevance 60/100

DOI: 10.1126/sciadv.aef5064PMID: 42536725Study type: preclinical (animal / model) study

TL;DR

This strategy establishes a modular platform for engineering instructive microenvironments that bridge molecular design and tissue-scale functionality.

Key findings

  • This design unites peptide self-assembly, receptor binding kinetics, and immunophenotypic outcomes in defining a molecular framework for tunable angiogenic materials.
  • This strategy establishes a modular platform for engineering instructive microenvironments that bridge molecular design and tissue-scale functionality.

What they did

Molecular dynamics simulations and solid-state nuclear magnetic resonance revealed that the coassembly mitigates steric interference between domains, enabling dense supramolecular packing while maintaining optimal receptor accessibility. The resulting SLan-K1 formulation preserves the secondary structure, activating canonical VEGFR2-MEK (mitogen-activated protein kinase kinase)-ERK (extracellular signal-regulated kinase). In vitro, these hydrogels induce endothelial proliferation; in vivo, they drive rapid neovascular infiltration and stable vascular integration in murine and rodent implants.

Full abstract (original)

Background: Therapeutic angiogenesis is constrained by the inability to localize, sustain, and finely tune vascular signaling. Here, we detail a supramolecular peptide system that enables angiogenic programming by decoupling mechanical integrity from receptor-level bioactivity. We integrate a vascular endothelial growth factor (VEGF)-mimetic amphiphile (SLan) with a mechanically robust β sheet peptide (K1) to yield injectable nanofiber hydrogels with tunable stiffness (100 to 1000 pascals) and preserved vascular endothelial growth factor receptor 2 (VEGFR2) affinity.

What they did: Molecular dynamics simulations and solid-state nuclear magnetic resonance revealed that the coassembly mitigates steric interference between domains, enabling dense supramolecular packing while maintaining optimal receptor accessibility. The resulting SLan-K1 formulation preserves the secondary structure, activating canonical VEGFR2-MEK (mitogen-activated protein kinase kinase)-ERK (extracellular signal-regulated kinase). In vitro, these hydrogels induce endothelial proliferation; in vivo, they drive rapid neovascular infiltration and stable vascular integration in murine and rodent implants.

Results & conclusions: This design unites peptide self-assembly, receptor binding kinetics, and immunophenotypic outcomes in defining a molecular framework for tunable angiogenic materials. This strategy establishes a modular platform for engineering instructive microenvironments that bridge molecular design and tissue-scale functionality.

Abstract © the authors / Science Advances (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1126/sciadv.aef5064 · PubMed 42536725.

Why it matters for pharma & biotech

  • Directly relevant to teams in targeted oncology / immuno-oncology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: targeted oncology / immuno-oncology

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Science Advances study find?

This strategy establishes a modular platform for engineering instructive microenvironments that bridge molecular design and tissue-scale functionality.

What type of study is this?

It is a preclinical (animal / model) study, published in Science Advances in 2026. Molecular dynamics simulations and solid-state nuclear magnetic resonance revealed that the coassembly mitigates steric interference between domains, enabling dense supramolecular packing while maintaining optimal receptor accessibility.

Where can I read the original paper?

The original is at the publisher via DOI 10.1126/sciadv.aef5064. PubMed ID: 42536725. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Dodd-O J, Shadpoor B, Roy A et al.. Programming angiogenesis with tunable assemblies of multifunctional peptides.. Science Advances (2026). DOI: 10.1126/sciadv.aef5064.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/programming-angiogenesis-with-tunable-assemblies-of-multifunctional-pept-ef5064/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides